Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKANNASDAQ:GRTXNASDAQ:MYMDNASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$1.17+0.9%$1.27$0.93▼$47.52$1.67M1.51336,816 shs13,772 shsGRTXGalera Therapeutics$0.02-0.4%$0.03$0.02▼$0.23$1.81M1.77112,280 shs38,245 shsMYMDMyMD Pharmaceuticals$0.22+23.4%$0.28$1.75▼$63.90$523K2.15134,123 shs18.36 million shsTNFATNF Pharmaceuticals$0.20-10.5%$0.28$0.16▼$2.16$2.00M2.13696,870 shs4.28 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda-4.92%-0.51%+0.01%-34.09%-83.52%GRTXGalera Therapeutics+1.26%+5.24%-10.74%-40.93%-86.24%MYMDMyMD Pharmaceuticals-8.83%-9.97%-35.23%-66.28%-92.33%TNFATNF Pharmaceuticals+23.39%+15.45%-18.45%-61.16%+22,049,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKANAkandaN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ATNFATNF Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$836.66K2.00N/AN/A($76.10) per share-0.02GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$32.28MN/A0.00∞N/AN/AN/AN/AN/AGRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%5/15/2025 (Estimated)MYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ATNFATNF Pharmaceuticals-$4M-$11.45N/A∞N/AN/A-180.71%-84.27%5/21/2025 (Estimated)Latest MYMD, TNFA, GRTX, and AKAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/A4/11/2025Q4 2024TNFATNF PharmaceuticalsN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.41N/AGRTXGalera TherapeuticsN/A9.749.74MYMDMyMD PharmaceuticalsN/A0.620.62TNFATNF PharmaceuticalsN/A1.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%GRTXGalera Therapeutics50.77%MYMDMyMD Pharmaceuticals9.64%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%GRTXGalera Therapeutics12.90%MYMDMyMD Pharmaceuticals2.12%TNFATNF Pharmaceuticals1.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda1101.43 million1.14 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableTNFATNF Pharmaceuticals610.13 million2.72 millionN/AMYMD, TNFA, GRTX, and AKAN HeadlinesRecent News About These CompaniesTNF Pharmaceuticals (TNFA) & Its Peers Financial ComparisonMay 15 at 2:57 AM | americanbankingnews.comComparing TNF Pharmaceuticals (TNFA) and Its PeersMay 14 at 2:43 AM | americanbankingnews.comReviewing TNF Pharmaceuticals (TNFA) and Its PeersMay 11, 2025 | americanbankingnews.comComparing TNF Pharmaceuticals (TNFA) & Its PeersMay 11, 2025 | americanbankingnews.comTNF Pharmaceuticals Amends Bylaws to Alter Voting RulesMay 9, 2025 | tipranks.comTNF Pharmaceuticals (TNFA) versus Its Peers Critical SurveyMay 9, 2025 | americanbankingnews.comTNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsMay 8, 2025 | businesswire.comCritical Survey: TNF Pharmaceuticals (TNFA) & Its PeersMay 8, 2025 | americanbankingnews.comReviewing TNF Pharmaceuticals (TNFA) & The CompetitionMay 8, 2025 | americanbankingnews.comAnalyzing TNF Pharmaceuticals (TNFA) & Its RivalsMay 8, 2025 | americanbankingnews.comReviewing TNF Pharmaceuticals (TNFA) and The CompetitionMay 6, 2025 | americanbankingnews.comCritical Review: TNF Pharmaceuticals (TNFA) and Its RivalsMay 5, 2025 | americanbankingnews.comTNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comTNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentApril 22, 2025 | finance.yahoo.comTNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishApril 22, 2025 | msn.comTNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025April 17, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. Common Stock (TNFA) Short InterestApril 3, 2025 | nasdaq.comTNF Pharmaceuticals faces Nasdaq delisting over priceMarch 23, 2025 | investing.comTNF Pharmaceuticals, Inc. Common StockMarch 20, 2025 | fxempire.comTNF Pharmaceuticals shares R&D progress on IsomyosamineMarch 12, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYMD, TNFA, GRTX, and AKAN Company DescriptionsAkanda NASDAQ:AKAN$1.17 +0.01 (+0.86%) As of 03:58 PM EasternAkanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-0.41%) As of 02:44 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.MyMD Pharmaceuticals NASDAQ:MYMD$0.22 +0.04 (+23.39%) As of 05/14/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.TNF Pharmaceuticals NASDAQ:TNFA$0.20 -0.02 (-10.52%) As of 04:00 PM EasternTNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
